Clinical Data

https://vyxeos.eu/wp-content/uploads/2020/01/VYXEOS_SEVERETY-ADVERSE-EVENTS.jpg

Rate of Adverse Events

https://vyxeos.eu/wp-content/uploads/2020/01/VXYEOS_GRAPH_Neutrophil.jpg

Neutrophil and Platelet Recovery

https://vyxeos.eu/wp-content/uploads/2020/01/VYXEOS_GRAPH_30-60-MORALITY.jpg

Mortality Rates

The overall frequency and severity of adverse events was comparable for Vyxeos Liposomal and conventional chemotherapy*1,2

  • In the Phase 3 study, Vyxeos Liposomal increased overall survival without increasing toxicity burden2
  • Vyxeos Liposomal was associated with an increased risk of prolonged neutropaenia and thrombocytopaenia, so patients may require additional monitoring.2,3 Refer to the summary of product characteristics for full details.3
  • Vyxeos Liposomal demonstrates lower 30- and 60-day mortality rates in comparison to conventional chemotherapy*2
    30-day mortality: 5.9% vs 10.6% (P=0.149)2
    60-day mortality: 13.7% vs 21.2% (P=0.097)2

References

  1. Vyxeos Liposomal (daunorubicin and cytarabine) liposome for injection. US Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf. Accessed January 2020
  2. Lancet JE et alJ Clin Oncol 2018; 36(26): 2684-2692
  3. Vyxeos Liposomal – Summary of Product Characteristics, October 2019
  4. Jazz Pharmaceuticals. Data on File (1)

 

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-1900008 | January 2020